{
  "success": true,
  "sourceFile": "C:\\Users\\panik\\Documents\\GitHub\\Protcol2USDMv3\\input\\trial\\NCT03125902_IMPASSION131\\NCT03125902_IMPASSION131_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Intent-to-Treat Population",
        "text": "All randomized patients, whether or not the assigned study treatment was received",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "ITT",
        "populationDescription": "All randomized patients, whether or not the assigned study treatment was received",
        "criteria": "All randomized patients"
      },
      {
        "id": "pop_2",
        "name": "PD-L1-positive subpopulation",
        "text": "Patients in the ITT population whose PD-L1 status was IC1/2/3 at the time of randomization",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "PD-L1-positive",
        "populationDescription": "Patients in the ITT population whose PD-L1 status was IC1/2/3 at the time of randomization",
        "criteria": "ITT population AND PD-L1 status IC1/2/3 at randomization"
      },
      {
        "id": "pop_3",
        "name": "Response-evaluable population",
        "text": "Patients in the ITT population with measurable disease at baseline",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "RE",
        "populationDescription": "Patients in the ITT population with measurable disease at baseline",
        "criteria": "ITT population AND measurable disease at baseline"
      },
      {
        "id": "pop_4",
        "name": "PD-L1-positive response-evaluable population",
        "text": "Patients in the PD-L1-positive subpopulation with measurable disease at baseline",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "PD-L1+ RE",
        "populationDescription": "Patients in the PD-L1-positive subpopulation with measurable disease at baseline",
        "criteria": "PD-L1-positive subpopulation AND measurable disease at baseline"
      },
      {
        "id": "pop_5",
        "name": "DOR-evaluable population",
        "text": "Patients in the ITT population with measurable disease at baseline and an objective response",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "DOR-evaluable",
        "populationDescription": "Patients in the ITT population with measurable disease at baseline and an objective response",
        "criteria": "ITT population AND measurable disease at baseline AND objective response"
      },
      {
        "id": "pop_6",
        "name": "C-DOR-evaluable population",
        "text": "Patients in the ITT population with measurable disease at baseline and a confirmed objective response",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "C-DOR-evaluable",
        "populationDescription": "Patients in the ITT population with measurable disease at baseline and a confirmed objective response",
        "criteria": "ITT population AND measurable disease at baseline AND confirmed objective response"
      },
      {
        "id": "pop_7",
        "name": "Patient reported outcome (PRO)-evaluable population",
        "text": "Patients in the ITT population with baseline PRO assessment and at least one post-baseline PRO assessment in the questionnaire of interest (European Organization for the Research and Treatment of Cancer [EORTC] Quality-of-Life Questionnaire [QLQ] C30, EORTC QLQ BR-23 or FACT-G).",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "PRO-evaluable",
        "populationDescription": "Patients in the ITT population with baseline PRO assessment and at least one post-baseline PRO assessment in the questionnaire of interest (European Organization for the Research and Treatment of Cancer [EORTC] Quality-of-Life Questionnaire [QLQ] C30, EORTC QLQ BR-23 or FACT-G).",
        "criteria": "ITT population AND baseline PRO assessment AND >=1 post-baseline PRO assessment"
      },
      {
        "id": "pop_8",
        "name": "Safety-evaluable population",
        "text": "Patients who received any amount of any study drug",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "Safety",
        "populationDescription": "Patients who received any amount of any study drug",
        "criteria": "Received any amount of study drug"
      },
      {
        "id": "pop_9",
        "name": "Pharmacokinetic (PK)-evaluable population",
        "text": "All patients who received any dose of study medication and who have at least one evaluable post-baseline PK sample",
        "populationType": "PK/PD",
        "instanceType": "AnalysisPopulation",
        "label": "PK-evaluable",
        "populationDescription": "All patients who received any dose of study medication and who have at least one evaluable post-baseline PK sample",
        "criteria": "Received any dose of study medication AND >=1 evaluable post-baseline PK sample"
      },
      {
        "id": "pop_10",
        "name": "Baseline ADA-evaluable population",
        "text": "All patients with at least one evaluable ADA assay result from a baseline sample",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "Baseline ADA",
        "populationDescription": "All patients with at least one evaluable ADA assay result from a baseline sample",
        "criteria": ">=1 evaluable ADA assay result from baseline sample"
      },
      {
        "id": "pop_11",
        "name": "Post-baseline ADA-evaluable population",
        "text": "All patients with at least one evaluable ADA assay result from at least one post-baseline sample",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "Post-baseline ADA",
        "populationDescription": "All patients with at least one evaluable ADA assay result from at least one post-baseline sample",
        "criteria": ">=1 evaluable ADA assay result from >=1 post-baseline sample"
      },
      {
        "id": "pop_12",
        "name": "China population",
        "text": "All patients enrolled in China (either in the global study or in the additional enrollment).",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "China",
        "populationDescription": "All patients enrolled in China (either in the global study or in the additional enrollment).",
        "criteria": "Enrolled in China"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Age",
        "code": "AGE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Age",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Continuous variable summarized using means, SDs, medians, ranges, and interquartile ranges"
      },
      {
        "id": "char_2",
        "name": "Tumor PD-L1 status",
        "code": "TUMOR_PD-L1_STATUS",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Tumor PD-L1 status",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "IC0 vs. IC1/2/3"
      },
      {
        "id": "char_3",
        "name": "Prior taxane treatment",
        "code": "PRIOR_TAXANE_TREATME",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Prior taxane treatment",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Yes vs. No"
      },
      {
        "id": "char_4",
        "name": "Presence of liver metastases",
        "code": "PRESENCE_OF_LIVER_ME",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Presence of liver metastases",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Yes vs. No"
      },
      {
        "id": "char_5",
        "name": "Region",
        "code": "REGION",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Region",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "North America vs. Western Europe/Australia vs. Eastern Europe/Asia Pacific vs. South America"
      }
    ],
    "summary": {
      "populationCount": 12,
      "characteristicCount": 5
    }
  }
}